GlassScriptPhysician profile
Son Van Nguyen
NPI 1508927716
$2,696.80
in general payments reported to CMS, 2019-2025
14 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $250 · 2021: $392 · 2022: $531 · 2023: $261 · 2024: $286 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.73 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $391.41 | 2019-2025 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $353.58 | 2019-2024 | |
| Glaxosmithkline, LLC. | $321.41 | 2019-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $308.22 | 2019-2025 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $268.86 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.79 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $245.36 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $119.28 | 2019-2025 | Zoryve |
| Amarin Pharma, INC. | $114.41 | 2021-2022 | |
| Abbvie INC. | $101.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $83.22 | 2019 | |
| Horizon Therapeutics Plc | $64.96 | 2019-2020 | |
| Mannkind Corporation | $35.40 | 2021 | |
| Amgen INC. | $25.76 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Son Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.